Orexo: Zubsolv Rx Data week 23

Research Update

2016-06-20

15:32

Latest data from Symphony Health Solutions, released last Friday, shows a w/w decline in tablets (volume) market share (4-week rolling average) by 0.05 percentage points to 5.46%. Compared with last week’s numbers the market share were down by 0.14 percentage points to 5.27%. From last week, Zubsolv TRx market share declined by 0.02 percentage points to 5.36%. The w/w 4-week rolling average were down by 0.04 percentage points to 5.48 %. The overall market (buprenorphine/naloxone products) grew by 6.7% (4-week rolling average) compared with last year. TRx shows a y/y 4-week rolling average growth rate of 7.8%.

KP

Klas Palin

Disclosures and disclaimers

Premium Plan required to unlock

Unlock companies to access

more high quality research.